Identification of effective natural PIK3CA H1047R inhibitors by computational study.

Naimeng Liu,Xiaye Lv,Dong Song,Xinhui Wang,Jing Wang,Ye Du,Zhen Guo,Xuan Li,Gaojing Dou,Haoqun Xie

doi:10.18632/aging.203409

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with a poor prognosis and a high recurrence rate. PIK3CA gene is frequently mutated in breast cancer, with PIK3CA H1047R as the hotspot mutation reported in TNBC. We used the ZINC database to screen natural compounds that could be structurally modified to develop drugs targeting the PIK3CA H1047R mutant protein in the PI3K pathway. The LibDock module showed that 2,749 compounds could strongly bind to the PIK3CA H1047R protein. Ultimately, the top 20 natural ligands with high LibDock scores were used for further analyses including assessment of ADME (absorption, distribution, metabolism, and excretion), toxicity, stability, and binding affinity. ZINC000004098448 and ZINC000014715656 were selected as the safest drug candidates with strong binding affinity to PIK3CA H1047R, no hepatotoxicity, less carcinogenicity, better plasma protein binding (PPB) properties, and enhanced intestinal permeability and absorption than the two reference drugs, PKI-402 and wortmannin. Moreover, their lower potential energies than those of PIK3CA H1047R confirmed the stability of the ligand-receptor complex under physiological conditions. ZINC000004098448 and ZINC000014715656 are thus safe and stable leads for designing drugs against PIK3CA H1047R as part of a targeted therapeutic approach for patients with TNBC.

Highlights

Its 4-year survival rate is only 77%, despite intensive treatment strategies such as surgery and chemotherapy [4]
ZINC000004098448 and ZINC000014715656 were selected as the safest drug candidates with strong binding affinity to PIK3CA H1047R, no hepatotoxicity, less carcinogenicity, better plasma protein binding (PPB)
With a high recurrence rate and poor prognosis, Triple-negative breast cancer (TNBC) accounts for nearly 10% to

Summary

Introduction

Its 4-year survival rate is only 77%, despite intensive treatment strategies such as surgery and chemotherapy [4]. This highlights the need to develop new and effective treatment strategies. Triple-negative breast cancer (TNBC) is a highly aggressive molecular subtype of breast cancer, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). 20% of the new breast cancer cases worldwide [1,2,3]. It is known to be frequently altered in human cancers, especially in breast cancer [5], with its overexpression associated with the activation of oncogenes such as PIK3CA and MTOR and inactivation (3HHM) was selected as the receptor to align these ligands.

Methods

Results

Discussion

Conclusion